These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target]. Guijarro C; Ruilope LM Med Clin (Barc); 2015 Jul; 145(2):67-9. PubMed ID: 26004275 [No Abstract] [Full Text] [Related]
3. [PCSK9 monoclonal antibody inhibition: current evidence and future perspectives of lipid-lowering therapy according to the available results from the ODYSSEY program]. Lettino M G Ital Cardiol (Rome); 2015 Apr; 16(4):211-6. PubMed ID: 25959756 [No Abstract] [Full Text] [Related]
4. PCSK9 inhibitors are go. Mullard A Nat Rev Drug Discov; 2015 Sep; 14(9):593. PubMed ID: 26323538 [No Abstract] [Full Text] [Related]
5. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease]. Christiansen MK; Jensen HK Ugeskr Laeger; 2015 Mar; 177(11):. PubMed ID: 25786699 [TBL] [Abstract][Full Text] [Related]
6. PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges. Norata GD; Tibolla G; Catapano AL Vascul Pharmacol; 2014 Aug; 62(2):103-11. PubMed ID: 24924410 [TBL] [Abstract][Full Text] [Related]
9. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Joseph L; Robinson JG Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907 [TBL] [Abstract][Full Text] [Related]
10. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value. Tice JA; Kazi DS; Pearson SD JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572 [No Abstract] [Full Text] [Related]
11. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors]. Avci A; Demir K; Altunkeser BB Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363 [TBL] [Abstract][Full Text] [Related]
12. How far down to push the LDL cholesterol? PCSK9 where statins fail. Simko V; Ginter E Bratisl Lek Listy; 2016; 117(4):193-4. PubMed ID: 27075380 [No Abstract] [Full Text] [Related]
14. The promises of PCSK9 inhibition. Petrides F; Shearston K; Chatelais M; Guilbaud F; Meilhac O; Lambert G Curr Opin Lipidol; 2013 Aug; 24(4):307-12. PubMed ID: 23817198 [TBL] [Abstract][Full Text] [Related]
15. [New drug development competition for LDL receptor]. Fujita T Nihon Yakurigaku Zasshi; 2014 May; 143(5):262. PubMed ID: 24813799 [No Abstract] [Full Text] [Related]
16. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
17. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs. Everett BM; Smith RJ; Hiatt WR N Engl J Med; 2015 Oct; 373(17):1588-91. PubMed ID: 26444323 [No Abstract] [Full Text] [Related]
18. Inhibition of PCSK9: is this the way forward for managing residual risk? Chowdhury SR; Rees A Curr Opin Lipidol; 2012 Oct; 23(5):509-10. PubMed ID: 22964999 [No Abstract] [Full Text] [Related]
19. PCSK9 antibodies for the treatment of hypercholesterolemia. Gouni-Berthold I; Berthold HK Nutrients; 2014 Dec; 6(12):5517-33. PubMed ID: 25470376 [TBL] [Abstract][Full Text] [Related]
20. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition--The Dream of Translational Medicine. Uppugunduri CR; George M J Cardiovasc Pharmacol; 2016 Feb; 67(2):191-2. PubMed ID: 26398165 [No Abstract] [Full Text] [Related] [Next] [New Search]